EU Malaria Fund

The EU Malaria Fund is a public-private partnership and impact investment vehicle dedicated to financing the development of innovative tools to prevent and treat malaria. Established by the European Union and the European Investment Bank, the fund addresses the market failure in global health by providing capital to high-risk, high-impact biotechnological projects. Its portfolio includes advanced vaccine candidates, monoclonal antibodies, and novel diagnostic platforms. Key stakeholders include the European Commission, the Bill & Melinda Gates Foundation, and the kENUP Foundation. By bridging the funding gap between late-stage research and commercialization, the fund aims to accelerate the eradication of malaria globally. It operates as a Luxembourg-based SICAV-SIF, focusing on projects with significant potential for public health impact in sub-Saharan Africa and other endemic regions.